The funds enable the Melbourne company to pay out its convertible note holder and avoid a further drawdown on that facility before its lead ALS drug reaches a pivotal trial readout next year.

OncoSil Medical has applied to regulators to manufacture its OncoSil device at a Macquarie Park, Sydney facility. The company said it hopes to start commercial production at the facility in the second half of the 2027 financial year.

Melbourne biotech Magellan Stem Cells is 17 years old and about to begin a pivotal Phase 3 trial of its stem cell treatment for osteoarthritis, a condition affecting more than 2 million Australians. Yet under legislation now before the Federal Parliament, it may also lose access to the refundable R&D Tax Incentive.

A small Melbourne company founded by two medical researchers has landed one of Australia's biggest potential licensing deals.

Neurizon Therapeutics has finished enrolling its pivotal ALS trial ahead of schedule. The US Food and Drug Administration has also told the Melbourne company that a single positive study could support approval of its lead drug, NUZ-001.

BCAL Diagnostics has secured a seat on Genetic Signatures' board, though it is only part of what it asked for. At an Extraordinary General Meeting, shareholders voted to appoint Dr John Melki to the GSS board but rejected the other three resolutions BCAL had put forward.

The Melbourne company dosed the first patient in its Beyond Harmony study of NTI164 on 21 September. All six sites across Victoria, Queensland, New South Wales, Tasmania and Western Australia are now open.

Australia's life sciences sector has converged on the Gold Coast for what organiser AusBiotech describes as the event's biggest edition yet, and for the first time, the peak body is running its three flagship conferences as a single, connected program.

Investors and Australian life sciences company leaders met on the Gold Coast this week for AusBiotech Invest, a curated forum designed to strengthen engagement between life sciences companies and capital.

CSL has named Deborah Waterhouse, a British pharmaceutical executive who previously led GSK in Australia, as its next chief executive and managing director.

Telix Pharmaceuticals has reaffirmed that it will pass US$1 billion in revenue and other income this year. Its third-quarter sales were consistent with the previous quarter, and it is working through a US$1.65 billion merger.

BioNTech has opened its clinical-scale mRNA manufacturing and research facility at La Trobe University's Bundoora campus, nearly three years after it first announced the plan.

As Australia's Biggest Week in Biotech approaches, AusBiotech is celebrating four emerging companies that have joined its growing national community through AusBiotech Connect, a membership designed to support the next generation of biotechnology, medical technology and health technology innovators.

Eleven life sciences companies will spend three minutes each making their case to investors on the Gold Coast this month. They will have no slides to lean on.

Australian biotech science has never been stronger, but the conditions around it are shifting. US drug pricing, China's rise and a rethink of American research funding are changing where medicines are discovered, developed and financed.

Tofflon Science and Technology Group will show a scale model of a modular CAR-T manufacturing facility at AusBiotech International 2026 on the Gold Coast.

Racura Oncology has been given the go-ahead to raise the dose in its HARNESS-1 lung cancer trial after a safety review found no dose-limiting toxicities in the first patients treated.